



IntegraGen and Twist Bioscience Expand Partnership with a Global Distribution Agreement for SIRIUS and MERCURY Genomic Data Analysis Tools Developed by IntegraGen

Twist Bioscience to offer SIRIUS and MERCURY to customers using its Human Core Exome Kit

ÉVRY, FRANCE – February 14, 2018 – IntegraGen (FR0010908723: ALINT - PEA-SME Eligible), a company specializing in the decoding of the human genome, today announced a global distribution agreement with Twist Bioscience for IntegraGen’s portfolio of genomic data analysis tools. The agreement includes distribution rights for **SIRIUS™**, an online Big Data solution that assists researchers to quickly and intuitively analyze exome data for Mendelian and oncology applications, and **MERCURY™**, an online biological interpretation tool for oncology intended to assist pathologists and oncologists transforming raw data obtained via high-throughput sequencing into a molecular report for translational and clinical research use.

“Pursuant to our recent agreement with IntegraGen where they became the first French genomic services provider to offer the Twist Core Exome kit, we are now becoming IntegraGen’s first global distributor of exome analysis tools,” said Emily M. Leproust, Ph.D., CEO of Twist Bioscience. “In addition, we look forward to offering customers using our Human Core Exome Kit the option of adding IntegraGen’s cloud-based platforms, Mercury and Sirius, for the analysis of germline or cancer samples.”

“The ability to offer the industry’s most efficient exome capture kit with our comprehensive exome data analysis tools, SIRIUS and MERCURY, creates an ideal combination for our customers. With this complete package, it has never been so easy, fast and cost-effective to translate biological samples into analyzed genomic data,” stated Bernard Courtieu, IntegraGen’s Chief Executive Officer. “We look forward to creating a leading genomic service offering based on the above and are extremely enthused to partner with Twist Bioscience, the leading technology provider in this field.”

About IntegraGen

IntegraGen is a company specializing in deciphering the human genome and producing relevant and easily interpretable data for academic and private laboratories. IntegraGen’s oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. As of December 31, 2016, IntegraGen had 38 employees and had generated revenue of €6.2 million in 2017. Based in Evry Genopole, IntegraGen also has an U.S. office in Cambridge, Massachusetts. IntegraGen is listed on Euronext Growth (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).

For more information, visit www.integragen.com

INTEGRAGEN CONTACTS

IntegraGen

Bernard COURTIEU
President and CEO

Laurence RIOT LAMOTTE
Chief Financial Officer
contact@integragen.com
Tel.: +33 (0)1 60 91 09 00

NewCap

Investor and Media Relations
Louis-Victor DELOUVRIER
integragen@newcap.eu
Tel.: +33 (0)1 44 71 98 53